ALX ONCOLOGY HOLDINGS INC (ALXO) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.72

From 52W high−34.62%

Volume5.06M

Market cap$235.07M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.72

From 52W high

−34.62%

Volume

5.06M

Market cap

$235.07M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.3x

P/E (TTM)

—

RSI (14)

34.7

MomentumView details →

1D Return

−2.30%

YTD Return

+51.33%

SummaryUpdated Jun 1, 2026

ALX Oncology Holdings Inc. (NASDAQ:ALXO) is a clinical-stage immuno-oncology biotechnology company founded in 2015 and headquartered in South San Francisco, California. The company went public in July 2020 and focuses on developing innovative cancer therapies that harness the body's immune system to fight tumors. ALX Oncology is currently advancing multiple drug candidates through clinical trials, with its lead program targeting a cellular pathway that cancer cells use to evade immune detection.

Ask drillr about ALX ONCOLOGY HOLDINGS INC →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.3x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−59.40%

ROA (TTM)

−50.30%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+48.64%

FCF YoY

+32.94%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+26.36%

EBITDA YoY

+30.79%

MomentumView details →

1D Return

−2.30%

YTD Return

+51.33%

1Y Return

+41.32%

RSI (14)

34.7

vs 50D SMA

−13.64%

vs 200D SMA

−7.14%

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

9.71x

Quick Ratio

9.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

9.04%

Beats (12Q)

6/12

Next Q EPS Est

−$0.13

Avg Surprise (4Q)

−5.41%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−80.89M

Op. CF (TTM)

−70.78M

Next earningsNov 6, 2026 →

Latest newsMore news →

ALX Oncology announced the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel.45d ago

ALX Oncology Holdings refinanced $10 million of existing debt and obtained an additional $20 million under a new $50 million loan facility, with $10 million uncommitted.46d ago

Similar companies

I-MabIMAB Compugen Ltd.CGEN Niagen Bioscience IncNAGE YD Bio Limited Ordinary SharesYDES Whitehawk Therapeutics IncWHWK Immunotech Biopharm Ltd06978.HK Find similar companies →

Latest newsMore news →

ALX Oncology announced the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel.45d ago ALX Oncology Holdings refinanced $10 million of existing debt and obtained an additional $20 million under a new $50 million loan facility, with $10 million uncommitted.46d ago ALX Oncology Holdings reported a Q2 2026 net loss of $17.97 million, or $0.13 per diluted share, with cash and investments of $153.4 million as of June 30, 2026.46d ago